38I:FRA
Intellia Therapeutics Inc
β¬10.26
arrow_downward
-4.11%(-0.44) 1D
4μ 30μΌ, μ€ν 10μ 0λΆ 0μ΄ GMT+2 · EUR
search
λͺ¨λ μ’
λͺ© μ½λ
1D
5D
1M
6M
YTD
1Y
5Y
μ΅λ
| μ’ λͺ© μ½λ | κ°κ²© | λ³λ | λ³λλ₯ (%) |
|---|
insights_auto38Iμ μ£Όμ ν΅κ³ μμ± μ€...
μκ°
β¬10.26
κ³ κ°
β¬10.26
μ κ°
β¬10.26
μκ°μ΄μ‘
17.64μ΅
νκ· κ±°λλ
272.00
κ±°λλ
0.00
52μ£Ό μ΅κ³ κ°
β¬24.34
52μ£Ό μ΅μ κ°
β¬6.00
μ§μ μ
377
λ΄μ€ κΈ°μ¬
μΉ μμ€ κΈ°λ°
Stock Titan
·
3μκ° μ
43 new Intellia employees get stock awards worth 208,850 shares
TipRanks
·
1μΌ μ
Intellia Therapeutics Prices Public Equity Offering to Fund Pipeline
StocksToTrade
·
1μΌ μ
NTLA Stock Draws Bulls After Phase 3 Gene-Editing Win
Timothy Sykes
·
2μΌ μ
NTLA Stock Slides As $150M Offering Signals Dilution Risk
νλ‘ν
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Ε ikΕ‘nys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
Intellia Therapeutics Incμ κ΄ν μ 보
CEOμ‘΄ λ μ€λλ₯΄λ
μ§μ377
창립μΌ2014
λ³Έμ¬μΌμλΈλ¦¬μ§, 맀μ¬μΆμΈμΈ , λ―Έκ΅
μ
μ’
-
μΉμ¬μ΄νΈintelliatx.com
AI μ½ν
μΈ μλ μ€λ₯κ° μμ μ μμ΅λλ€. μμΈν μμ보기